Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Cathie Wood’s ARK ETFs have made their daily trades for Thursday, 24 April 2025, with a notable sell-off in Adaptive Biotechnologies Corp (NASDAQ:ADPT) and a purchase in Beam Therapeutics Inc (NASDAQ:BEAM), among other moves.
Leading the trades was ARK’s sale of 76,437 shares of Adaptive Biotechnologies through its ARKG ETF, totaling approximately $564,105. This continues a recent trend, as ARK has been reducing its position in ADPT throughout the past week, with substantial sales on Wednesday and Tuesday as well.
Conversely, ARK showed continued interest in Beam Therapeutics, buying 4,732 shares through ARKG, valued at around $94,024. This follows a pattern of accumulation in BEAM, with ARK having bought shares in the company on multiple occasions in the preceding days.
Meanwhile, ARK also trimmed its holdings in other stocks. The ARKW ETF sold a modest 100 shares of tech giant Microsoft Corp (NASDAQ:MSFT) for $37,439 and 2,799 shares of UiPath Inc (NYSE:PATH) for $30,425. These sales are part of a broader sell-off in PATH, with ARK offloading shares of the company consistently over the past week.
In a more significant move, ARK’s ARKK ETF parted ways with 35,510 shares of Veracyte Inc (NASDAQ:VCYT), cashing out $1,117,499. This sale was also in line with recent activity, as ARK sold shares of VCYT in the preceding days.
The daily trade report provides a window into ARK’s strategic adjustments and can offer investors insight into Cathie Wood’s current investment outlook. It’s evident from the ongoing transactions that ARK is actively managing its portfolio, capitalizing on market movements and repositioning its investments in the biotech and tech sectors.
Investors and market watchers often look to ARK’s trades for signals about emerging trends and the investment firm’s confidence in specific sectors or companies. The continued investment in Beam Therapeutics suggests a bullish stance on the company’s prospects, while the repeated sales of Adaptive Biotechnologies may indicate a strategic shift away from the stock.
ARK’s trade activity is closely monitored as it can have broader implications for market sentiment and the performance of the sectors in which the ETFs are invested. As always, investors should consider their own research and risk tolerance when looking at the movements of prominent investment firms like Cathie Wood’s ARK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.